Description
ADCC-Enhanced anti-CD40 (18 Competitor Antibodies) (APX005) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD40 (18 Competitor Antibodies) antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD40
Full Name
CD40 molecule, TNF receptor superfamily member 5
Background
This gene is a member of the TNF-receptor superfamily. The encoded protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. AT-hook transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions. Adaptor protein TNFR2 interacts with this receptor and serves as a mediator of the signal transduction. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. Mutations affecting this gene are the cause of autosomal recessive hyper-IgM immunodeficiency type 3 (HIGM3). Multiple alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
Alternative Names
CD40; CD40 molecule, TNF receptor superfamily member 5; p50; Bp50; CDW40; TNFRSF5; tumor necrosis factor receptor superfamily member 5; CD40L receptor; CD40 type II isoform; B cell-associated molecule; B cell surface antigen CD40; CD40 antigen (TNF receptor superfamily member 5); nerve growth factor receptor-related B-lymphocyte activation molecule
Gene ID
958
UniProt ID
Q5ZPR3
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with CD40 include Immunodeficiency With Hyper-Igm, Type 3 and Immunodeficiency With Hyper-Igm, Type 1.
Related Pathways
Its related pathways are Transcriptional misregulation in cancer and NF-KappaB Family Pathway.
Function
Receptor for TNFSF5/CD40LG (PubMed:31331973). Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion (By similarity).
Field of research
Cell Biology and Cellular Response antibody; Developmental Biology antibody; Immune System antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody
Post-translational modifications
1.Glycosylation at Asn153 and Asn180 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
APX005
Description
APX005 is a promising immunotherapeutic capable of destroying tumor and tumor stroma through several distinct mechanisms of action. APX005 is a strong CD40 agonist that can stimulate anti-tumor immune responses by binding to CD40 molecules on the antigen presenting cells and activating immune co-stimulatory pathways to boost tumor-specific immunity. Furthermore, APX005 can also trigger direct tumor killing.
Antibody Indication
Cancer
